MedTrace Logo

Pilot Study Lp299v Supplementation in Chronic Heart Failure

NCT05752760 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-01

No results posted yet for this study

Summary

The goal of this study is to determine the impact of 12 weeks of Lp299v supplementation (20 million cfu/day vs. placebo) on exercise capacity, circulating biomarkers of cardiac remodeling, quality of life, and vascular endothelial function in humans with heart failure and reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) who have evidence of residual inflammation based on an elevated C-reactive protein level. This will be done in the setting of a randomized, double-blind, placebo-controlled trial.

Conditions

Interventions

OTHER

Lactobacillus Plantarum 299v Freeze Dried Capsule

The intervention is a probiotic lactobacillus that is contained in food products in the US

OTHER

Freeze Dried Potato Starch Capsule

The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.

Sponsors & Collaborators

  • Advancing a Healthier Wisconsin

    collaborator UNKNOWN

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Michael E Widlansky, MD · Medical College of Wisconsin

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2025-03-31
Completion
2026-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05752760 on ClinicalTrials.gov